1136-82-9

Basic information

• Product Name: 2-BROMO-N-(1-NAPHTHYL)ACETAMIDE
• Synonyms: 2-BROMO-N-(1-NAPHTHYL)ACETAMIDE;acetamide, 2-bromo-N-1-naphthalenyl-;2-bromo-N-naphthalen-1-ylacetamide;2-bromo-N-naphthalen-1-yl-ethanamide;Acetamide, N-(1-naphthyl)-2-bromo-
• CAS NO: 1136-82-9
• Molecular Formula: C₁₂H₁₀BrNO
• Molecular Weight: 264.12
• Mol File: 1136-82-9.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-BROMO-N-(1-NAPHTHYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-N-(1-NAPHTHYL)ACETAMIDE(1136-82-9)
• EPA Substance Registry System: 2-BROMO-N-(1-NAPHTHYL)ACETAMIDE(1136-82-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1136-82-9(Hazardous Substances Data)

Upstream product

• 134-32-7 1-amino-naphthalene 
• 79-08-3 bromoacetic acid 
• 22118-09-8 2-bromoacetyl chloride 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 1265918-98-6 1-(2,6-diisopropylphenyl)-3-[2-(naphthalen-1-ylamino)-2-oxoethyl]-1H-imidazol-3-ium bromide 

Relevant articles and documents

Design, synthesis, anticancer and antioxidant activities of amide linked 1,4-disubstituted 1,2,3-triazoles

To explore anticancer and antioxidant agents with improved potency, we synthesized a series of amide linked 1,4-disubstituted 1,2,3-triazoles through click chemistry approach. The structure of synthesized triazoles were characterized by- FTIR, 1H NMR, 13C NMR spectroscopy and HRMS. All the synthesized compounds were screened for their anticancer activity against four different cell lines- PC3 (prostate cancer), A549 (lung cancer), MIAPACA (liver cancer), Fr2 (Breast epithelial), reflecting compounds 7e and 7f to possess good activity. The antioxidant activity was evaluated by using stable free radical 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay and compound 7d showed promising activity having IC50 value 1.61 μg/ml. Molecular docking studies of compounds 7e and 7f was carried out in active site of human epidermal growth factor receptor 2 revealed high binding affinities and within toxicity limits. The experimental results were in good agreement with docking studies. In-silico ADME studies of synthesized compounds also have good dispositional profile and are patient compliant, may be potential future candidates for anticancer treatment.

Synthesis, characterization, crystal and molecular structure and theoretical study of N-(naphthalen-1-yl)-2-(piperidin-1-yl) acetamide, a selective butyrylcholinesterase inhibitor

In this study, we reported for the first time the crystalline and molecular structure of the compound N-(naphthalen-1-yl) -2- (piperidin-1-yl) acetamide. The synthesis of the compound was carried out by amidation using a coupling reagent (N, N'-diisopropylcarbodiimide) and subsequently amination. The compound was experimentally characterized by UV-visible spectroscopy, 13C-NMR, 1H-NMR, melting point, and X-ray diffraction technique. In addition, we include here, theoretical studies on boundary molecular orbitals, descriptors global reactivity, natural bond orbital analysis, Hirshfeld surface analysis, energy framework and molecular docking. Interestingly, acetamide shows a keto form in the solid state, as reported in similar monosubstituted acetamide compounds. The dihedral angles are negligible, being essentially coplanar between the fragment. Additionally, inhibitory activity studies were carried out for the enzymes acetylcholinesterase and butyrylcholinesterase, obtaining an IC50 of 426.14 ± 18.54 μM and 5.12 ± 0.02 μM, respectively, thus having significant selectivity for butyrylcholinesterase with an IC50 lower than that reported for the reference compound galantamine (7.96 ± 0.8 μM). Our consistent molecular coupling analyzes show the formation of a more stable complex between compound 5 and butyricholinesterase due to the complementary interactions of compound 5′s naphthyl ring with residues Trp 231 and Phe 329 compared to the complex formed with acetylcholinesterase.

Pyrazoline tethered 1,2,3-triazoles: Synthesis, antimicrobial evaluation and in silico studies

A new series of pyrazoline-amide linked 1,2,3-triazole hybrids was wisely designed and synthesized using 1,3-dipolar cycloaddition between pyrazoline linked alkynes and 2-bromo-N-arylacetamide. All the newly synthesized compounds were evaluated in vitro against different microbial strains viz. Escherichia coli, Bacillius subtilis, Staphylococcus aureus, Aspergillus niger, and Candida albicans. Pyrazoline linked terminal alkynes (4a–c) showed MIC = 0.062–0.078 μmol/mL against different bacterial and fungal strain. However, pyrazoline-amide linked 1,2,3-triazole hybrids (6a-6t) showed MIC = 0.0229–0.050 μmol/mL. Compound 6e exhibited better efficacy against E. coli and both the fungal strains compared to standard drugs used. Docking studies of the most potent compounds were carried out against bacterial DNA Gyr A and fungal 14α-steroldemethylase were also performed. The binding potential of 4a and 6e with both the target using molecular dynamics simulations was also investigated.